Loracarbef

From WikiProjectMed
Jump to navigation Jump to search
Loracarbef
Names
Trade namesLorabid
  • (6R,7S)-7-[[(2S)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Clinical data
WHO AWaRe
External links
AHFS/Drugs.comMonograph
MedlinePlusa601206
Pharmacokinetics
Protein binding25%
Identifiers
CAS Number
  • 76470-66-1 checkY
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
ATC code
Chemical and physical data
FormulaC16H16ClN3O4
Molar mass349.77 g·mol−1
3D model (JSmol)
  • Cl\C3=C(/C(=O)O)N2C(=O)[C@@H](NC(=O)[C@@H](c1ccccc1)N)[C@H]2CC3.O
  • InChI=1S/C16H16ClN3O4.H2O/c17-9-6-7-10-12(15(22)20(10)13(9)16(23)24)19-14(21)11(18)8-4-2-1-3-5-8;/h1-5,10-12H,6-7,18H2,(H,19,21)(H,23,24);1H2/t10-,11-,12+;/m1./s1 checkY
  • Key:GPYKKBAAPVOCIW-HSASPSRMSA-N checkY

Loracarbef is an antibiotic.[1]


It is in the second-generation cephalosporin family of medications.[2]

It is a carbacephem. Loracarbef is a synthetic "carba" analog of cefaclor, and is more stable.

History

Loracarbef received FDA approval in 1991 and it was marketed under the trade name Lorabid. Its use was discontinued in 2006.[citation needed]

Usage & Indications

Loracarbef was used to treat infections of the lungs, maxillary sinuses, throat, skin, and urinary tract.[3]

Spectrum of Activity

Loracarbef had broad spectrum effectiveness against both gram-negative and gram-positive bacteria, including those precipitating infections of the respiratory tract, sinuses, tonsils, skin, urinary tract, and kidneys. It was of specific use in those infections caused by E. Coli, S. pyogenes, S. Aureus, S. saprphyticus, S. penumoniae, H. influenza, and M. catarrhalis. [4]

Side effects

Diarrhea is the most common adverse effect with loracarbef. Side effects are more frequently seen with children under the age of twelve.

References

  1. ↑ Biedenbach DJ, Jones RN (February 1994). "Predictive accuracy of disk diffusion test for Proteus vulgaris and Providencia species against five newer orally administered cephalosporins, cefdinir, cefetamet, cefprozil, cefuroxime, and loracarbef". Journal of Clinical Microbiology. 32 (2): 559–62. doi:10.1128/JCM.32.2.559-562.1994. PMC 263078. PMID 8150976.
  2. ↑ Beauduy, Camille E.; Winston, Lisa G. (2020). "43. Beta-lactam and other cell wall - & membrane - active antibiotics". In Katzung, Bertram G.; Trevor, Anthony J. (eds.). Basic and Clinical Pharmacology (15th ed.). New York: McGraw-Hill. p. 832. ISBN 978-1-260-45231-0. Archived from the original on 2021-10-10. Retrieved 2021-11-30.
  3. ↑ "Lorabid (Loracarbef): Uses, Dosage, Side Effects, Interactions, Warning". RxList. Archived from the original on 2018-01-16. Retrieved 2020-06-15.
  4. ↑ "Loracarbef". www.drugbank.ca. Archived from the original on 2019-06-16. Retrieved 2020-06-15.

External links

Stub icon

This systemic antibiotic-related article is a stub. You can help MDWiki by expanding it.

Retrieved from "https://mdwiki.org/w/index.php?title=Loracarbef&oldid=1379374"